Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH to Fund Collaborations with Industry to Identify New Uses for Existing Compounds

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Crowdsourcing initiative will enable exploration of potential treatments in eight disease areas.

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer’s disease, Duchenne muscular dystrophy and schizophrenia.

The collaborative pilot initiative, called Discovering New Therapeutic Uses for Existing Molecules, is led by the National Center for Advancing Translational Sciences (NCATS) and funded by the NIH Common Fund.

The process of developing a new therapeutic is long and difficult. The average length of time from target discovery to approval of a new drug is more than 13 years, and the failure rate exceeds 95 percent.

This failure rate means, however, that many existing partially developed compounds could be advanced to clinical trials more quickly than starting from scratch.

“With thousands of diseases remaining untreatable, there is a sense of urgency to accelerate the pace at which discoveries are transformed into therapies for patients,” said Health and Human Services Secretary Kathleen Sebelius.

Sebelius continued, “This program helps forge partnerships between the pharmaceutical industry and the biomedical research community to work together to tackle problems that are beyond the scope of any one organization or sector.”

“Innovative, collaborative approaches that improve the therapeutic pipeline are crucial for success,” said NIH Director Francis S. Collins, M.D., Ph.D. “This unique collaboration between academia and industry holds the promise of trimming years from the long and expensive process of drug development.”

AbbVie (formerly Abbott); AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Research & Development, LLC; Pfizer; and Sanofi are participating in the pilot phase of the program.

NCATS launched this initiative in 2012 to help re-engineer the research pipeline using an innovative strategy to identify new uses for compounds that have undergone significant research and development by industry, including safety testing in humans.

The center crowdsourced the industry compounds to academic researchers nationwide to gain ideas for new therapeutic uses with the ultimate goal of developing new treatments for patients.

The program also tested newly created template agreements, which enabled negotiations to be completed in fewer than 11 weeks, versus a typical timeline of a year or more.

“Public-private collaborations are crucial for successful translation; no one organization can succeed alone,” said NCATS Director Christopher P. Austin, M.D. “This initiative has created a marketplace to connect academic researchers with potential new drugs, as well as template agreements that streamline the process by limiting the amount of negotiation required before a project can begin.”

Each award recipient will test a selected compound for its effectiveness against a previously unexplored disease or condition. The eight disease areas represented are alcohol dependence, Alzheimer’s disease, calcific aortic valve stenosis (a condition in which the heart valve hardens and makes it difficult to pump blood out of the heart), nicotine dependence, peripheral artery disease, schizophrenia and two rare diseases: Duchenne muscular dystrophy and the progressive lung disease lymphangioleiomyomatosis.

For more details about each project, please visit http://www.ncats.nih.gov/therapeutics-projects.html. The projects, award recipient principal investigators and industry partners are:

The efficacy and safety of a selective estrogen receptor beta agonist (LY500307)
Academic Partner: Alan Breier, M.D., Indiana University, Indianapolis
Industry Partner: Eli Lilly and Company

Fyn inhibition by AZD0530 for Alzheimer’s disease
Academic Partners: Stephen M. Strittmatter, M.D., Ph.D.; Haakon Berge Nygaard, M.D., Ph.D.; and Christopher H. Van Dyck, M.D., Yale University, New Haven, Conn.
Industry Partner: AstraZeneca

Medication development of a novel therapeutic for smoking cessation
Academic Partners: Darlene H. Brunzell, Ph.D., Virginia Commonwealth University, Richmond and Kenneth Alan Perkins, Ph.D., University of Pittsburgh
Industry Partner: Janssen Research & Development, LLC

A novel compound for alcoholism treatment: A translational strategy
Academic Partner: Fatemeh Akhlaghi, Pharm.D., Ph.D., University of Rhode Island, Kingston
NIH Intramural Partner: Lorenzo Leggio, M.D., Ph.D., M.Sc., National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse
Industry Partner: Pfizer

Partnering to treat an orphan disease: Duchenne muscular dystrophy
Academic Partners: Kathryn R. Wagner, M.D., Ph.D., Kennedy Krieger Institute, Baltimore
and Stanley C. Froehner, Ph.D., University of Washington, Seattle
Industry Partner: Sanofi

Reuse of ZD4054 for patients with symptomatic peripheral artery disease (PAD)
Academic Partner: Brian H. Annex, M.D., University of Virginia, Charlottesville
Industry Partner: AstraZeneca

Therapeutic strategy for lymphangioleiomyomatosis (LAM)
Academic Partner: N. Tony Eissa, M.D., Baylor College of Medicine, Houston
Industry Partner: AstraZeneca

Therapeutic strategy to slow progression of calcific aortic valve stenosis
Academic Partners: Jordan D. Miller, Ph.D.; Maurice Enriquez-Sarano, M.D.; and
Hartzell V. Schaff, M.D., Mayo Clinic, Rochester, Minn.
Industry Partner: Sanofi

Translational neuroscience optimization of GlyT1 inhibitor for cognitive impairments associated with schizophrenia
Academic Partner: John H. Krystal, M.D., Yale University, New Haven, Conn.
Industry Partner: Pfizer

These cooperative agreements will fund projects for researchers to conduct pre-clinical validation and additional safety studies as needed. If specific milestones are met, clinical feasibility studies or proof-of-concept clinical trials will be initiated to test whether the selected compounds may be effective as treatments for other diseases. The projects will be supported for up to three years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Wednesday, December 07, 2016
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Wednesday, December 07, 2016
Uncovering Cerebral Malaria’s Deadly Agents
NIH scientists film inside mouse brains to uncover biology behind the disease.
Wednesday, December 07, 2016
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
Food Additives Promote Inflammation, Colon Cancer
Dietary emulsifiers promoted colon cancer in a mouse model by altering gut microbes and increasing gut inflammation.
Wednesday, November 23, 2016
Protein-Folding Gene Helps Heal Wounds
Researchers identified a protein that dramatically accelerates wound healing in animal models.
Wednesday, November 23, 2016
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Monday, November 21, 2016
Big Data for Infectious Disease Surveillance
NIH-led effort examines use of big data from health records and other digital sources for uses in infectious disease surveillance.
Tuesday, November 15, 2016
Potential Therapies Against Drug-Resistant Bacteria Identified
Researchers create new identification method for drug and drug combinations that may combat resistant infections.
Thursday, November 10, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Genetic Markers Predict Malaria Treatment Failure
By comparing 297 parasite genomes to a reference malaria parasite genome, researchers have identified two genetic markers that are strongly associated with the parasites’ ability to resist piperaquine.
Monday, November 07, 2016
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Wednesday, November 02, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!